Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intraocular Pressure Clear all
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?

NCT00799994
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 21, 2026, 3:41 AM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Results available

24-hour IOP-lowering Effect of 0.01% Bimatoprost

NCT01271686
View directory record Official record
Conditions
Intraocular Pressure, Glaucoma, Ocular Hypertension
Interventions
0.01% bimatoprost
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 21, 2026, 3:41 AM EDT
Enrolling by invitation No phase listed Observational

Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty

NCT07073937
View directory record Official record
Conditions
Glaucoma, Open Angle, MIGS, Minimally Invasive Glaucoma Surgery, Canaloplasty, Intraocular Pressure (IOP), Cataract Surgery, Surgical Technique, Minimally Invasive Surgical Technique, Glaucoma
Interventions
Retrospective chart review
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tonometry Precision and Accuracy During PROSE Scleral Lens Wear: A Pilot Study

NCT04308941
View directory record Official record
Conditions
Intraocular Pressure and PROSE Lens
Interventions
Intraocular pressure
Diagnostic Test
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional

Evaluating Home Testing Devices for the Management of Glaucoma

NCT05325996
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Central Corneal Thickness On IOP Using Various Tonometers

NCT00570791
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Tonometer
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional Results available

Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease

NCT01798966
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Caffeinated Coffee on Intraocular Pressure

NCT01364207
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Brimonidine

NCT03959176
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational

Classification of Heart Failure With Preserved Ejection Fraction

NCT01030991
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Diastolic Heart Failure
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01410188
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
OPA-6566, Placebo, Latanoprost
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Artesia, California • Glendale, California • Roswell, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 21, 2026, 3:41 AM EDT
Not listed Not applicable Interventional

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

NCT06313749
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions
Minimally Invasive Micro Sclerostomy Device
Device
Lead sponsor
Sanoculis Ltd
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

NCT01284309
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational

Non-Invasive EndoPAT Increases Diagnostic Yield of CAD by Coronary Angiography

NCT01581671
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 21, 2026, 3:41 AM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear

NCT04442464
View directory record Official record
Conditions
Ocular Hypertension
Interventions
Scleral Lens
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparative Study of the Topcon Tonometers CT-800 and TRK-2P and the Haag-Streit Goldmann Manual Tonometer and Topcon SP-1P

NCT03439774
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Topcon CT-800, Topcon TRK-2P
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 21, 2026, 3:41 AM EDT
Not listed No phase listed Observational

Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit

NCT01618123
View directory record Official record
Conditions
Myocardial Infarction, Death, Cerebrovascular Accident, Congestive Heart Failure, Angina Pectoris
Interventions
Not listed
Lead sponsor
Sheba Medical Center
Government
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 21, 2026, 3:41 AM EDT
Completed No phase listed Observational

Study of Eye Pressure as a Predictor of Intracranial Pressure in the Acutely Head-Injured Population

NCT00534157
View directory record Official record
Conditions
Craniocerebral Trauma
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2007 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

NCT00828477
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Xibrom, Nevanac
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
3340 6 Mile Rd Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Results available

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 21, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

NCT00657241
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Valsartan
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 21, 2026, 3:41 AM EDT